Biblio

Found 9 results
Filters: Keyword is Neoadjuvant Therapy  [Clear All Filters]
2023
Parker BA, Shatsky RA, Schwab RB, Wallace AM, Wolf DM, Hirst GL, Brown-Swigart L, Esserman LJ, Veer LJ van 't, Ghia EM, et al. Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial. Breast Cancer Res Treat. 2023 ;199(2):281-291.
Magbanua MJesus M, Veer Lvan 't, Clark AS, A Chien J, Boughey JC, Han HS, Wallace A, Beckwith H, Liu MC, Yau C, et al. Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT study. Breast Cancer Res Treat. 2023 ;198(2):383-390.
2022
Mukhtar R, W Symmans F, Esserman LJ. Association of Residual Cancer Burden After Neoadjuvant Therapy and Event-Free Survival in Breast Cancer-Reply. JAMA Oncol. 2022 ;8(4):1.
Osdoit M, Yau C, W Symmans F, Boughey JC, Ewing CA, Balassanian R, Chen Y-Y, Krings G, Wallace AM, Zare S, et al. Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial. JAMA Surg. 2022 ;157(11):1034-1041.
Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher RI, Lee PRong Evely, Zhu Z, Magbanua MJ, Sayaman R, O'Grady N, et al. Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. Cancer Cell. 2022 ;40(6):609-623.e6.
Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy A-S, Laé M, Reyal F, Sonke GS, et al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol. 2022 ;23(1):149-160.
Yau C, Osdoit M, Esserman LJ, W Symmans F. Survivorship after neoadjuvant chemotherapy - Authors' reply. Lancet Oncol. 2022 ;23(3):e96.
Marczyk M, Mrukwa A, Yau C, Wolf D, Chen Y-Y, Balassanian R, Nanda R, Parker BA, Krings G, Sattar H, et al. Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials. Ann Oncol. 2022 ;33(8):814-823.
Noordhoek I, Bastiaannet E, de Glas NA, Scheepens J, Esserman LJ, Wesseling J, Scholten AN, Schröder CP, Elias SG, Kroep JR, et al. Validation of the 70-gene signature test (MammaPrint) to identify patients with breast cancer aged ≥ 70 years with ultralow risk of distant recurrence: A population-based cohort study. J Geriatr Oncol. 2022 ;13(8):1172-1177.